Impact of quality control matrix effect: Application to the calculation of uncertainty of measurement in one-stage clotting factor VIII assay

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 5, 2010, Pages 498-501

  Sobas, Frédéric ^a   Benattar, Norbert ^b   Bellisario, Audrey ^c   Marin, Sylvie ^a   Nougier, Christophe ^a   Lienhart, Anne ^a   Négrier, Claude ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Cryopep   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

Matrix effects; one stage clotting factor VIII assay; quality controls; uncertainty of measurement

Indexed keywords

BLOOD CLOTTING FACTOR 8; BOVINE SERUM ALBUMIN;

ARTICLE; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD SAMPLING; CALCULATION; CONSENSUS; DIAGNOSTIC ACCURACY; DILUTION; HEMOPHILIA; HUMAN; MEASUREMENT; PRIORITY JOURNAL; QUALITY CONTROL; UNCERTAINTY;

ANIMALS; BIOLOGICAL ASSAY; BLOOD COAGULATION TESTS; ENDOTHELIAL CELLS; FACTOR VIII; HEMOPHILIA A; MICE; QUALITY CONTROL; UNCERTAINTY;

EID: 77954628898     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328338dbd3     Document Type: Article

References (13)

1. ISO. 15189 Standard medical laboratories special requirements about quality and proficiency. Geneva: ISO; 2008.
2. ISO. Guide to expression of uncertainty in measurement. 101 Geneva: ISO; 1995.
3. Kristiansen J. Description of a generally applicable model for the evaluation of uncertainty of measurement in clinical chemistry. Clin Chem Lab Med 2001; 39:920-931.
4. Fraser C, Kallner A, Kenny D, Petersen PH. Introduction: strategies to set global quality specifications in laboratory medicine. Scand J Clin Lab Invest 1999; 59:477-478. (Pubitemid 30056735)
5. Kallner A.Quality specifications based on the uncertainty of measurements. Scand J Clin Lab Invest 1999; 59:513-516.
6. Linko S, Ö rnemark U, Kessel R, Taylor PDP. Evaluation of uncertainty of measurement in routine clinical chemistry. Clin Chem Lab Med 2002; 40:391-398.
7. Thienpont LM, Stockl D, Kratochvila J, Friedecky B, Budina M. Pilot external quality assessment survey for post-market vigilance of in vitro diagnostic medical devices and investigation of trueness of participants' results. Clin Chem Lab Med 2003; 41:183-186.
8. Sobas F, Mazliak L, Bellisario A, Lefranc M, Lienhart A, Nougier C, et al. Determining the adequate number of internal quality control levels: the example of coagulation factor VIII assay. Blood Coagul Fibrinol 2008; 19:433-437.
9. Meijer PDM, de Maat MPM, Kluft C, Haverkate F, Van Houwelingen HC. Long-term analytical performance of hemostasis field methods as assessed by evaluation of the results of an external quality assesment program for antithrombin. Clin Chem 2002; 48:1011-1015.
10. Hardisty RM, Macpherson MJC. A one-stage factor VIII (antihemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrag 1962; 7:215-229.
11. Meijer PDM, Verbruggen B. Assessment of the between-laboratory and the long-term within-laboratory analytical variation for factor VIII testing. Poster no. 04P055 WFH congress Istanbul 2008.
12. Lippi G, Franchini M, Favaloro E. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. Blood Coagul Fibrinol 2009; 20:1-3.
13. Kasper CK, Boylen AL, Ewing NP, Luck JV, Jr, Dietrich SL. Hematologic management of hemophilia A for surgery. JAMA 1985; 253:1279-1283.